Literature DB >> 15304366

Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies.

Mahmood Tavallaie1, Alexandre Chenal, Daniel Gillet, Yannik Pereira, Maria Manich, Maryse Gibert, Stephanie Raffestin, Michel R Popoff, Jean Christophe Marvaud.   

Abstract

The botulinum neurotoxin A C-terminal fragment (Hc), which mediates the binding of the toxin to neuronal cell surface receptors, comprises two subdomains, Hc-N (amino acids 873-1095) and Hc-C (amino acids 1096-1296). In order to define the minimal fragment of Hc carrying protective antigenic properties, Hc, Hc-N and Hc-C have been produced as recombinant proteins in Escherichia coli, and have been tested for their antigenicity in mouse protection assays. Hc, Hc-N and Hc-C induced similar antibody levels as shown by ELISA. However, a single immunization with Hc (10 microg) fully protected mice challenged with 10(3) mouse lethal dose 50 of toxin, whereas Hc-N, Hc-C, or Hc-N plus Hc-C did not give any protection. Triple immunizations with Hc-N or Hc-C were necessary to induce a higher level of protection. Circular dichroism and fluorescence studies showed that the isolated subdomains were folded and stable. However, an intense near-UV dichroic signal was only observed in the Hc spectrum, revealing a highly structured interface between both subdomains. Taken together, the results show that the generation of protective antibodies requires the whole Hc domain and especially the native structure of the interfacial region between Hc-N and Hc-C.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304366     DOI: 10.1016/j.febslet.2004.06.094

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

1.  Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting.

Authors:  Mengfei Ho; Li-Hsin Chang; Melissa Pires-Alves; Baskaran Thyagarajan; Jordan E Bloom; Zhengrong Gu; Karla K Aberle; Sasha A Teymorian; Yuka Bannai; Steven C Johnson; Joseph J McArdle; Brenda A Wilson
Journal:  Protein Eng Des Sel       Date:  2010-11-04       Impact factor: 1.650

2.  Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.

Authors:  Christelle Mazuet; Julie Dano; Michel R Popoff; Christophe Créminon; Hervé Volland
Journal:  PLoS One       Date:  2010-08-26       Impact factor: 3.240

3.  Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Authors:  James S Henkel; William H Tepp; Amanda Przedpelski; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

4.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

5.  DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge.

Authors:  Veronica L Scott; Daniel O Villarreal; Natalie A Hutnick; Jewell N Walters; Edwin Ragwan; Khalil Bdeir; Jian Yan; Niranjan Y Sardesai; Adam C Finnefrock; Danilo R Casimiro; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  An atypical outbreak of food-borne botulism due to Clostridium botulinum types B and E from ham.

Authors:  Christelle Mazuet; Jean Sautereau; Christine Legeay; Christiane Bouchier; Philippe Bouvet; Michel R Popoff
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

Review 7.  Protein Structure Facilitates High-Resolution Immunological Mapping.

Authors:  Madison Zuverink; Joseph T Barbieri
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

8.  Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

Authors:  Michael R Baldwin; William H Tepp; Christina L Pier; Marite Bradshaw; Mengfei Ho; Brenda A Wilson; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

9.  Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A.

Authors:  Julie Prigent; Christelle Mazuet; Didier Boquet; Patricia Lamourette; Hervé Volland; Michel R Popoff; Christophe Créminon; Stéphanie Simon
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

10.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.